title: Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis.
abstract: Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-γ (PPAR-γ), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-κB and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment.
authors.affiliation: Department of Critical Care Medicine, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.affiliation: Department of General Surgery, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.
authors.forename: Zhaopeng
authors.initials: Z
authors.lastname: Yan
authors.affiliation: Department of Critical Care Medicine, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.
authors.forename: Xingmao
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Critical Care Medicine, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.
authors.forename: Kaiqiang
authors.initials: K
authors.lastname: Ji
authors.affiliation: Department of Critical Care Medicine, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.
authors.forename: Haiyuan
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Critical Care Medicine, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.
authors.forename: Bin
authors.initials: B
authors.lastname: Zang
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology* / Q000517:prevention & control*; D000818:Animals; D015153:Blotting, Western; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D006949:Hyperlipidemias / Q000150:complications; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008297:Male; D010195:Pancreatitis / Q000150:complications*; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone
keywords: Rosiglitazone; apoptosis; hyperlipidemic pancreatitis; inflammation; renal injury